Join Now! Role of Genetics in Clinical Settings

Dear Dr. Renukaprasad A R, Adopting clinical genetic tools such as next-generation sequencing promises unprecedented opportunities for improving patient care. However, there are still some barriers, such as high cost, complex datasets, and practical challenges related to physician support and education, that must be addressed for optimal patient outcomes. Join Dr. Snehal Mallakmir in an exclusive MasterSeries session, where she will share her insights on "Understanding Clinical Genetics in Multidisciplinary Settings" TODAY at 3:00 PM IST. Session Highlights:  Current Scenario  General Indications Newborn screening- Blood spot  Epigenetics Tune in & Watch Live Docplexus is one of the world's largest online communities Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*

India : AIIMS Ransomware Attack Causes Patient Data at Risk of Leak, & More

Hi Renukaprasad A R, Top Stories of the Day: Polio Cases on the Rise in Indonesia and Pakistan UAE: Premarital Screening for 570 Genetic Conditions India: Government Identifies Antimicrobial Resistance as a Key Priority Scientists Discover Tailor-Made Pocket Feature of Coronaviruses AIIMS Ransomware Attack Causes Patient Data at Risk of Leak Webinar: Understanding Clinical Genetics in Multidisciplinary Settings Healthcare headlines that matter, brought to you every day by Docplexus Health Minute! Watch News Docplexus is one of the world's largest online communities Pune - 411045, India Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*

Abemaciclib in EBC: Recent Updates from India

Dear Dr. Renukaprasad A R, Do you know that Ramiven ® is approved in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive early breast cancer (EBC) patients at high risk of recurrence? Several clinical trials suggested that up to 30% of HR+ HER2- node-positive EBC patients with high-risk clinical characteristics may experience distant recurrence. Therefore, superior treatment options are needed to prevent early recurrence and the development of metastases. Abemaciclib is the first CDK4/6 inhibitor to establish a significant improvement in HR+ HER2- node-positive EBC patients at high risk of early recurrence. Be a part of an exclusive session where renowned international and national oncology experts discuss their perspectives on the high unmet needs in EBC and the benefits that Ramiven® for high-risk EBC patients in India. Have you missed the Ramiven ® EBC launch program? Not an issue! We have saved the recording just for YOU! We hope the discussion will give you insights into the recent advancements in the field of breast cancer and will help you in your practice. Click to Watch Docplexus is one of the world's largest online communities Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*

Latest Trends in Anti-HER2 Breast Cancer Therapies

Dear Dr. Renukaprasad A R, HER2 levels strongly correlate with carcinogenesis, making it an adverse prognostic marker. Although HER2 is an excellent target for breast cancer treatment, resistance to anti-HER2 drugs in the advanced stages of cancer remains a challenge. Several kinds of research are ongoing to determine the effectiveness of anti-HER2 treatment alone and in combination with other drugs for HER2-positive metastatic breast cancer. For more insights on the latest developments in anti-HER2 therapy for breast cancer, join the proficient oncologist, Dr. Uma Dangi, in an exclusive webinar, TODAY at 3:00 PM IST. Click to Join Docplexus is one of the world's largest online communities Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*

Clinical Genetics in Multidisciplinary Settings

Dear Dr. Renukaprasad A R, The past two decades have seen major shifts in our ability to sequence genetic information. Adopting clinical genetics tools such as next-generation sequencing by specialist clinics has made it easier to diagnose rare genetic disorders. It is prudent to understand the potential opportunities in clinical genetics and its associated challenges. Join Dr. Snehal Mallakmir in an exclusive MasterSeries session, where she will share her insights on "Understanding Clinical Genetics in Multidisciplinary Settings" on 30th November 2022, 3:00 PM IST onwards. Click to Know More Docplexus is one of the world's largest online communities Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*

Stay Updated with the Latest in AGC Management

Dear Dr. Renukaprasad A R, Advanced gastric cancer (AGC) is a leading cause of cancer-related deaths worldwide. Several treatment modalities have been investigated, but only a few exhibit clinically meaningful results. Ramucirumab is used as monotherapy and in combination with paclitaxel for AGC in patients with disease progression after chemotherapy. In case you missed our earlier session on the therapeutic potential of Ramucirumab in AGC patients, grab this opportunity to be part of the next session today, from 9:30 PM IST onwards. Looking forward to your active participation in this informative discussion! Highlights: Opening remarks - Dr. Abdullah Alsharm, KSA ESMO guideline updates for treatment of AGC - Prof. Stefano Cascinu, Italy Post-IO 2L mGC case presentation - Dr. Akhil Kapoor, India Nutrition assessment and support for gastric cancer management - Ms. Lucy Eldridge, UK Panel Discussion - All Speakers Join Now Docplexus is one of the world's largest online communities Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*